CNS therapeutics · Oncology therapeutics
Sumitomo Dainippon Pharma
A Japanese pharmaceutical company developing psychiatric-neurological and oncology treatments. Nikkei 225 constituent. Baseline node ahead of value-chain research; promoted to a full node once AI question demand is observed.
Business categories Pharmaceuticals & Biotechnology · Biopharma & Life Sciences · primary Oncology & ADCs · Biopharma & Life Sciences
Other companies in the same category
- Pharmaceuticals & Biotechnology: Alnylam Pharmaceuticals · Regeneron Pharmaceuticals · Moderna · AbbVie · Lilly (Eli)
- Oncology & ADCs: Bristol-Myers Squibb Company · Merck & Co. · LigaChem Biosciences · Daiichi Sankyo · HLB
4506.T Updated Jul 11, 2026 2 AI consumers· 1 recurring
Annual return · 2026-10-09'21-25.5%'22-25.1%'23-51.9%'24+40.6%'25+276.6%YTD-30.7%
Money in ▸·
Sumitomo Dainippon Pharma~¥320B
▸ Money out·
Financials & Segments
- Total revenue · ~¥320B (FY2024)
- Segments · Pharmaceuticals
Revenue from
No refined links yet.
Pays to
No refined links yet.